IGF-1 Monitoring and Dose Optimization With Long-Acting Growth Hormone Analogs

In the second segment, Joshua Yang, MD, focuses on dose optimization and monitoring strategies for patients receiving long-acting growth hormone (GH) analogs, with particular attention to the interpretation of IGF-1 levels. He explains that clinicians transitioning from daily to long-acting GH must adapt their monitoring practices because the pharmacokinetics of weekly formulations differ substantially from those of daily injections. Whereas daily GH therapy generally produces relatively flat IGF-1 profiles over 24 hours, long-acting analogs are characterized by a weekly peak and trough pattern, making the timing of blood draws critical for accurate assessment.

Yang stresses that each long-acting GH analog has distinct pharmacokinetic properties, molecular structure, and dosing parameters, and that these products are not interchangeable. As a result, clinicians must be familiar with product-specific recommendations regarding when to obtain IGF-1 measurements—whether at or near peak, trough, or at a timepoint that best approximates average weekly exposure.

He notes that, for the long-acting products currently in use, consensus and practical experience often support measuring IGF-1 around day 4 after the injection to approximate mean exposure over the dosing interval. When patients cannot access the laboratory on the ideal day, validated calculators can assist in estimating average IGF-1 exposure from off-schedule draws.

Despite the emphasis on precise timing, Yang reiterates that IGF-1 is one component of a broader clinical assessment rather than a sole determinant of management decisions. In his approach, IGF-1 data are interpreted alongside growth velocity, duration of treatment, pubertal status, and indicators of adherence. For example, suboptimal height velocity in the context of appropriate IGF-1 levels may prompt a reassessment of adherence, comorbidities, or pubertal progression rather than immediate dose escalation.

By integrating pharmacokinetic understanding with individualized clinical judgment, Yang suggests that clinicians can safely optimize long-acting GH dosing while maintaining a focus on both efficacy and long-term safety.